Similar to our studies, Wadas et al. did not observe higher tumor uptake with antagonist 64Cu-CB-TE2A-sst2-ANT compared to agonist 64Cu-CB-TE2A-Y3-TATE when using the endogenously expressing sstr2 model, AR42J (Wadas et al. 2008). The gene discussed is SSTR2; the disease is neoplasm.